English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe award is annually bestowed upon a distinguished expert who has made significant contributions to cancer prevention and control research or practice. It will be presented at the 2025 ASCO Annual Meeting, taking place May 30 – June 3 in Chicago.
A medical oncologist, Domchek’s research focuses on improving the genetic evaluation and medical care of individuals with inherited risk factors for cancer. As director of the Basser Center—established in 2012 as the first comprehensive center for the research, treatment, and prevention of cancers related to BRCA1 and BRCA2 genetic mutations—she leads a team dedicated to advancing innovative genetics research and providing education and genetic counseling to families. She is particularly interested in developing cancer interception strategies, including the possibility of immune-interception, for those with a genetic susceptibility, and is the principal investigator of an ongoing clinical trial testing an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations.
In her seminal work, Domchek demonstrated that risk-reducing salpingo-oophorectomy, a surgery to remove the ovaries and fallopian tubes, is associated with improved survival in BRCA1 and BRCA2 mutation carriers. She has been critical in the development of PARP inhibitors in BRCA-associated cancers, where these targeted therapies have been shown to reduce the risk of recurrence and improve overall survival. Her work has also addressed the real-world complexity of the clinical application of germline genetics, particularly with multigene panel testing.
“Dr. Domchek’s work has made an incredible impact on countless individuals and their families who are affected by inherited cancer-associated gene mutations,” said Alison Loren, MD, chief of Hematology-Oncology. “We’re proud to see her efforts recognized through this special award from her peers at ASCO.”
Domchek is a Fellow of the ASCO, an elected member of the National Academy of Medicine, the Association of American Physicians (AAP), and the American Society of Clinical Investigation (ASCI), and has authored or co-authored more than 450 articles appearing in the New England Journal of Medicine, Journal of the American Medical Association, and the Journal of Clinical Oncology, among others.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.
